Radiation Oncology Journal

  • 제36권4호
  • /
  • Pages.317-324
  • /
  • 2018
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Postoperative radiotherapy for mucoepidermoid carcinoma of the major salivary glands: long-term results of a single-institution experience

  • Park, Geumju (Department of Radiation Oncology, Inje University Haeundae Paik Hospital, Inje University College of Medicine) ;
  • Lee, Sang-wook (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine)
  • 투고 : 2018.08.28
  • 심사 : 2018.11.26
  • 발행 : 2018.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: This study aimed to evaluate the long-term survival outcomes and prognostic factors that affect the clinical outcomes of patients who underwent surgery and postoperative radiotherapy for major salivary gland mucoepidermoid carcinoma (MEC). Materials and Methods: We retrospectively reviewed the clinical data of 44 patients who underwent surgery followed by radiotherapy for primary MEC of the major salivary glands between 1991 and 2014. The median follow-up period was 9.8 years (range, 0.8 to 23.8 years). Results: The overall outcomes at 5 and 10 years were 81.5% and 78.0% for overall survival (OS), 86.2% and 83.4% for disease-free survival, 90.6% and 87.6% for locoregional recurrence-free survival, and both 90.5% for distant metastasis-free survival (DMFS). Histologic grade was the only independent predictor of OS (low vs. intermediate vs. high; hazard ratio = 3.699; p = 0.041) in multivariate analysis. A poorer survival was observed among patients with high-grade tumors compared with those with non-high-grade tumors (5-year OS, 37.5% vs. 91.7%, p < 0.001; 5-year DMFS, 46.9% vs. 100%, p < 0.001). Conclusion: Surgery and postoperative radiotherapy resulted in excellent survival outcomes for patients with major salivary gland MEC. However, high-grade tumors contributed to poor DMFS and OS. Additional aggressive strategies for improving survival outcomes should be developed for high-grade MEC.

키워드

참고문헌

  1. Eveson JW, Cawson RA. Salivary gland tumours: a review of 2410 cases with particular reference to histological types, site, age and sex distribution. J Pathol 1985;146:51-8.
  2. Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 1986;8:177-84.
  3. Seethala RR. An update on grading of salivary gland carcinomas. Head Neck Pathol 2009;3:69-77.
  4. Luna MA. Salivary mucoepidermoid carcinoma: revisited. Adv Anat Pathol 2006;13:293-307.
  5. Goode RK, Auclair PL, Ellis GL. Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. Cancer 1998;82:1217-24.
  6. Guzzo M, Andreola S, Sirizzotti G, Cantu G. Mucoepidermoid carcinoma of the salivary glands: clinicopathologic review of 108 patients treated at the National Cancer Institute of Milan. Ann Surg Oncol 2002;9:688-95.
  7. Kokemueller H, Brueggemann N, Swennen G, Eckardt A. Mucoepidermoid carcinoma of the salivary glands: clinical review of 42 cases. Oral Oncol 2005;41:3-10.
  8. Rapidis AD, Givalos N, Gakiopoulou H, et al. Mucoepidermoid carcinoma of the salivary glands. Review of the literature and clinicopathological analysis of 18 patients. Oral Oncol 2007;43:130-6.
  9. Nance MA, Seethala RR, Wang Y, et al. Treatment and survival outcomes based on histologic grading in patients with head and neck mucoepidermoid carcinoma. Cancer 2008;113:2082-9.
  10. Chen AM, Lau VH, Farwell DG, Luu Q, Donald PJ. Mucoepidermoid carcinoma of the parotid gland treated by surgery and postoperative radiation therapy: clinicopathologic correlates of outcome. Laryngoscope 2013;123:3049-55.
  11. Garden AS, el-Naggar AK, Morrison WH, Callender DL, Ang KK, Peters LJ. Postoperative radiotherapy for malignant tumors of the parotid gland. Int J Radiat Oncol Biol Phys 1997;37:79-85.
  12. Terhaard CH, Lubsen H, Van der Tweel I, et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck 2004;26:681-93.
  13. Kaur J, Goyal S, Muzumder S, Bhasker S, Mohanti BK, Rath GK. Outcome of surgery and post-operative radiotherapy for major salivary gland carcinoma: ten year experience from a single institute. Asian Pac J Cancer Prev 2014;15:8259-63.
  14. North CA, Lee DJ, Piantadosi S, Zahurak M, Johns ME. Carcinoma of the major salivary glands treated by surgery or surgery plus postoperative radiotherapy. Int J Radiat Oncol Biol Phys 1990;18:1319-26.
  15. Theriault C, Fitzpatrick PJ. Malignant parotid tumors: prognostic factors and optimum treatment. Am J Clin Oncol 1986;9:510-6.
  16. Renehan A, Gleave EN, Hancock BD, Smith P, McGurk M. Longterm follow-up of over 1000 patients with salivary gland tumours treated in a single centre. Br J Surg 1996;83:1750-4.
  17. Lopes MA, Santos GC, Kowalski LP. Multivariate survival analysis of 128 cases of oral cavity minor salivary gland carcinomas. Head Neck 1998;20:699-706.
  18. Ghosh-Laskar S, Murthy V, Wadasadawala T, et al. Mucoepidermoid carcinoma of the parotid gland: factors affecting outcome. Head Neck 2011;33:497-503.
  19. Aro K, Leivo I, Makitie AA. Management and outcome of patients with mucoepidermoid carcinoma of major salivary gland origin: a single institution's 30-year experience. Laryngoscope 2008;118:258-62.
  20. Pires FR, de Almeida OP, de Araujo VC, Kowalski LP. Prognostic factors in head and neck mucoepidermoid carcinoma. Arch Otolaryngol Head Neck Surg 2004;130:174-80.
  21. Batsakis JG, Luna MA. Histopathologic grading of salivary gland neoplasms. I. Mucoepidermoid carcinomas. Ann Otol Rhinol Laryngol 1990;99(10 Pt 1):835-8.
  22. Brandwein MS, Ivanov K, Wallace DI, et al. Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. Am J Surg Pathol 2001;25:835-45.
  23. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-52.
  24. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-44.
  25. Tanvetyanon T, Qin D, Padhya T, et al. Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg 2009;135:687-92.
  26. Pederson AW, Salama JK, Haraf DJ, et al. Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol 2011;3:31.
  27. Mifsud MJ, Tanvetyanon T, Mccaffrey JC, et al. Adjuvant radiotherapy versus concurrent chemoradiotherapy for the management of high-risk salivary gland carcinomas. Head Neck 2016;38:1628-33.
  28. Gebhardt BJ, Ohr JP, Ferris RL, et al. Concurrent chemoradiotherapy in the adjuvant treatment of highrisk primary salivary gland malignancies. Am J Clin Oncol 2018;41:888-93.
  29. Spiro RH, Huvos AG, Berk R, Strong EW. Mucoepidermoid carcinoma of salivary gland origin: a clinicopathologic study of 367 cases. Am J Surg 1978;136:461-8.
  30. McHugh CH, Roberts DB, El-Naggar AK, et al. Prognostic factors in mucoepidermoid carcinoma of the salivary glands. Cancer 2012;118:3928-36.
  31. Granic M, Suton P, Mueller D, Cvrljevic I, Luksic I. Prognostic factors in head and neck mucoepidermoid carcinoma: experience at a single institution based on 64 consecutive patients over a 28-year period. Int J Oral Maxillofac Surg 2018;47:283-8.

피인용 문헌

  1. Treatment Outcome of a Combined Dose-Escalated Treatment Regime With Helical TomoTherapy® and Active Raster-Scanning Carbon Ion Boost for Adenocarcinomas of the Head and Neck vol.9, pp.None, 2018, https://doi.org/10.3389/fonc.2019.00755
  2. Minimal acute toxicity from proton beam therapy for major salivary gland cancer vol.59, pp.2, 2018, https://doi.org/10.1080/0284186x.2019.1698764
  3. Overall and cause-specific survival for mucoepidermoid carcinoma of the major salivary glands: Analysis of 2210 patients vol.11, pp.12, 2020, https://doi.org/10.5306/wjco.v11.i12.1029